Abstract
To compare differences in evolutionary progressions from Mild Cognitive Impairment (MCI) to dementia of Alzheimers type (DAT) or to vascular dementia (VaD) versus normal aging, subjects identified as MCI or as cognitively normal (CN) during standard cognitive evaluations among a large epidemiological study designed to determine prevalence and incidence of dementia and its major subtypes in Beijing, China were re-examined after an interval of approximately 3 years, repeating the same investigation protocol as at baseline. MCI subjects meeting criteria for dementia and the two major subtypes, DAT and VaD were identified at follow-up evaluation. Annual conversion rates for combined dementias and for major subtypes of DAT and VaD, from MCI, were compared with conversion rates among CN subjects. Relative risks for conversion from MCI to major subtypes of dementia were also compared with CN subjects by Cox regression models. 175 MCI and 400 CN subjects were identified at baseline. Among 121 MCI subjects available at followup, 51 were diagnosed with dementia (29 with DAT, 18 with VaD and 4 with other dementias), compared with 14(10 DAT, 3 VaD and 1 other type dementia) diagnosed as dementia among 281 CN subjects available at follow-up. Annual conversion rates calculated from MCI to all dementias, compared with conversion rates from CNs, were 14.1% versus 1.6%. Specifically for DAT, annual conversion rates were 8.0% versus 1.1% and for VaD were 5.0% versus 0.3%. Relative risks for developing all dementias, DAT and VaD among MCI subjects were 9, 6 and 5 times greater than among CN subjects. Conversion rates among MCI subjects to dementia, and major subtypes, for elderly Chinese residents of Beijing were comparable with results reported among similar studies worldwide. Risks of developing dementia, and major subtypes, among MCI subjects in Beijing were significantly higher than among normal subjects. Identification of MCI among elderly populations provides the possibilities for dementia prevention and treatment within prodromal stages.
Keywords: Mild cognitive impairment (MCI), dementia of Alzheimer type (DAT), vascular dementia (VaD), conversion rate
Current Alzheimer Research
Title: Progression of Mild Cognitive Impairment to Alzheimers or Vascular Dementia Versus Normative Aging Among Elderly Chinese
Volume: 2 Issue: 5
Author(s): Juebin Huang, John S. Meyer, Zhenxin Zhang, Jing Wei, Xia Hong, Jianmin Wang, Hongbo Wen, Wenjie Wu, Jixing Wu and Munir H. Chowdhury
Affiliation:
Keywords: Mild cognitive impairment (MCI), dementia of Alzheimer type (DAT), vascular dementia (VaD), conversion rate
Abstract: To compare differences in evolutionary progressions from Mild Cognitive Impairment (MCI) to dementia of Alzheimers type (DAT) or to vascular dementia (VaD) versus normal aging, subjects identified as MCI or as cognitively normal (CN) during standard cognitive evaluations among a large epidemiological study designed to determine prevalence and incidence of dementia and its major subtypes in Beijing, China were re-examined after an interval of approximately 3 years, repeating the same investigation protocol as at baseline. MCI subjects meeting criteria for dementia and the two major subtypes, DAT and VaD were identified at follow-up evaluation. Annual conversion rates for combined dementias and for major subtypes of DAT and VaD, from MCI, were compared with conversion rates among CN subjects. Relative risks for conversion from MCI to major subtypes of dementia were also compared with CN subjects by Cox regression models. 175 MCI and 400 CN subjects were identified at baseline. Among 121 MCI subjects available at followup, 51 were diagnosed with dementia (29 with DAT, 18 with VaD and 4 with other dementias), compared with 14(10 DAT, 3 VaD and 1 other type dementia) diagnosed as dementia among 281 CN subjects available at follow-up. Annual conversion rates calculated from MCI to all dementias, compared with conversion rates from CNs, were 14.1% versus 1.6%. Specifically for DAT, annual conversion rates were 8.0% versus 1.1% and for VaD were 5.0% versus 0.3%. Relative risks for developing all dementias, DAT and VaD among MCI subjects were 9, 6 and 5 times greater than among CN subjects. Conversion rates among MCI subjects to dementia, and major subtypes, for elderly Chinese residents of Beijing were comparable with results reported among similar studies worldwide. Risks of developing dementia, and major subtypes, among MCI subjects in Beijing were significantly higher than among normal subjects. Identification of MCI among elderly populations provides the possibilities for dementia prevention and treatment within prodromal stages.
Export Options
About this article
Cite this article as:
Huang Juebin, Meyer S. John, Zhang Zhenxin, Wei Jing, Hong Xia, Wang Jianmin, Wen Hongbo, Wu Wenjie, Wu Jixing and Chowdhury H. Munir, Progression of Mild Cognitive Impairment to Alzheimers or Vascular Dementia Versus Normative Aging Among Elderly Chinese, Current Alzheimer Research 2005; 2 (5) . https://dx.doi.org/10.2174/156720505774932223
DOI https://dx.doi.org/10.2174/156720505774932223 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Granular Non-Fibrillar Aggregates and Toxicity in Alzheimer’s Disease
Current Alzheimer Research Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology The Association of Folic Acid Deficiency and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets Biosafety of Lentiviral Vectors
Current Gene Therapy Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Association between Periodontal Health Status and Cognitive Abilitie s. The Role of Cytokine Profile and Systemic Inflammation
Current Alzheimer Research In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Current Bioactive Compounds Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
Current Molecular Pharmacology Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Primary Progressive Aphasia-Defining Genetic and Pathological Subtypes
Current Alzheimer Research GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Protein Oxidation and Proteolytic Signalling in Aging
Current Pharmaceutical Design Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research